Quintão Nara L M, Passos Giselle F, Medeiros Rodrigo, Paszcuk Ana F, Motta Fabiana L, Pesquero João B, Campos Maria M, Calixto João B
Department of Pharmacology, Center of Biological Sciences, Universidade Federal de Santa Catarina, CEP 88049-900, Florianópolis, Brazil.
J Neurosci. 2008 Mar 12;28(11):2856-63. doi: 10.1523/JNEUROSCI.4389-07.2008.
The relevance of kinin B(1) (B(1)R) and B(2) (B(2)R) receptors in the brachial plexus avulsion (BPA) model was evaluated in mice, by means of genetic and pharmacological tools. BPA-induced hypernociception was absent in B(1)R, but not in B(2)R, knock-out mice. Local or intraperitoneal administration of the B(2)R antagonist Hoe 140 failed to affect BPA-induced mechanical hypernociception. Interestingly, local or intraperitoneal treatment with B(1)R antagonists, R-715 or SSR240612, dosed at the time of surgery, significantly reduced BPA-evoked mechanical hypernociception. Intrathecal or intracerebroventricular administration of these antagonists, at the surgery moment, did not prevent the hypernociception. Both antagonists, dosed by intraperitoneal or intrathecal routes (but not intracerebroventricularly) 4 d after the surgery, significantly inhibited the mechanical hypernociception. At 30 d after the BPA, only the intracerebroventricular treatment effectively reduced the hypernociception. A marked increase in B(1)R mRNA was observed in the hypothalamus, hippocampus, thalamus, and cortex at 4 d after BPA and only in the hypothalamus and cortex at 30 d. In the spinal cord, a slight increase in B(1)R mRNA expression was observed as early as at 2 d. Finally, an enhancement of B(1)R protein expression was found in all the analyzed brain structures at 4 and 30 d after the BPA, whereas in the spinal cord, this parameter was augmented only at 4 d. The data provide new evidence on the role of peripheral and central kinin B(1)R in the BPA model of neuropathic pain. Selective B(1)R antagonists might well represent valuable tools for the management of neuropathic pain.
通过基因和药理学工具,在小鼠中评估了激肽B(1)(B(1)R)和B(2)(B(2)R)受体在臂丛神经撕脱(BPA)模型中的相关性。在B(1)R基因敲除小鼠中不存在BPA诱导的痛觉过敏,但在B(2)R基因敲除小鼠中存在。局部或腹腔注射B(2)R拮抗剂Hoe 140未能影响BPA诱导的机械性痛觉过敏。有趣的是,在手术时给予B(1)R拮抗剂R-715或SSR240612进行局部或腹腔治疗,可显著降低BPA诱发的机械性痛觉过敏。在手术时鞘内或脑室内注射这些拮抗剂并不能预防痛觉过敏。两种拮抗剂在手术后4天通过腹腔或鞘内途径(而非脑室内)给药,可显著抑制机械性痛觉过敏。在BPA后30天,只有脑室内治疗能有效减轻痛觉过敏。在BPA后4天,下丘脑、海马体、丘脑和皮质中观察到B(1)R mRNA显著增加,而在30天时仅在下丘脑和皮质中观察到增加。在脊髓中,早在2天时就观察到B(1)R mRNA表达略有增加。最后,在BPA后4天和30天,在所有分析的脑结构中发现B(1)R蛋白表达增强,而在脊髓中,该参数仅在4天时增加。这些数据为外周和中枢激肽B(1)R在神经性疼痛的BPA模型中的作用提供了新的证据。选择性B(1)R拮抗剂很可能是治疗神经性疼痛的有价值工具。